These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

13607 related articles for article (PubMed ID: 10076571)

  • 1. Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor.
    Asano M; Yukita A; Suzuki H
    Jpn J Cancer Res; 1999 Jan; 90(1):93-100. PubMed ID: 10076571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo.
    Asano M; Yukita A; Matsumoto T; Hanatani M; Suzuki H
    Hybridoma; 1998 Apr; 17(2):185-90. PubMed ID: 9627059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
    Gorski DH; Beckett MA; Jaskowiak NT; Calvin DP; Mauceri HJ; Salloum RM; Seetharam S; Koons A; Hari DM; Kufe DW; Weichselbaum RR
    Cancer Res; 1999 Jul; 59(14):3374-8. PubMed ID: 10416597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody.
    Kondo S; Asano M; Suzuki H
    Biochem Biophys Res Commun; 1993 Aug; 194(3):1234-41. PubMed ID: 7688963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo.
    Borgström P; Bourdon MA; Hillan KJ; Sriramarao P; Ferrara N
    Prostate; 1998 Apr; 35(1):1-10. PubMed ID: 9537593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.
    Borgström P; Gold DP; Hillan KJ; Ferrara N
    Anticancer Res; 1999; 19(5B):4203-14. PubMed ID: 10628376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.
    Asano M; Yukita A; Matsumoto T; Kondo S; Suzuki H
    Cancer Res; 1995 Nov; 55(22):5296-301. PubMed ID: 7585591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo.
    Soh EY; Eigelberger MS; Kim KJ; Wong MG; Young DM; Clark OH; Duh QY
    Surgery; 2000 Dec; 128(6):1059-65;discussion 1065-6. PubMed ID: 11114643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.
    Presta LG; Chen H; O'Connor SJ; Chisholm V; Meng YG; Krummen L; Winkler M; Ferrara N
    Cancer Res; 1997 Oct; 57(20):4593-9. PubMed ID: 9377574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice.
    Kanai T; Konno H; Tanaka T; Baba M; Matsumoto K; Nakamura S; Yukita A; Asano M; Suzuki H; Baba S
    Int J Cancer; 1998 Sep; 77(6):933-6. PubMed ID: 9714067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.
    Jayson GC; Zweit J; Jackson A; Mulatero C; Julyan P; Ranson M; Broughton L; Wagstaff J; Hakannson L; Groenewegen G; Bailey J; Smith N; Hastings D; Lawrance J; Haroon H; Ward T; McGown AT; Tang M; Levitt D; Marreaud S; Lehmann FF; Herold M; Zwierzina H;
    J Natl Cancer Inst; 2002 Oct; 94(19):1484-93. PubMed ID: 12359857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.
    Gerber HP; Kowalski J; Sherman D; Eberhard DA; Ferrara N
    Cancer Res; 2000 Nov; 60(22):6253-8. PubMed ID: 11103779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
    McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
    J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model.
    Melnyk O; Zimmerman M; Kim KJ; Shuman M
    J Urol; 1999 Mar; 161(3):960-3. PubMed ID: 10022734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma.
    Dagnaes-Hansen F; Rasmussen LM; Tilton R; Denner L; Flyvbjerg A
    Anticancer Res; 2003; 23(2B):1625-30. PubMed ID: 12820432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors.
    Zielke A; Middeke M; Hoffmann S; Colombo-Benkmann M; Barth P; Hassan I; Wunderlich A; Hofbauer LC; Duh QY
    Surgery; 2002 Dec; 132(6):1056-63; discussion 1063. PubMed ID: 12490855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
    Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with vascular endothelial growth factor neutralizing antibody and mitomycin C on human gastric cancer xenograft.
    Matsumoto K; Konno H; Tanaka T; Baba M; Kanai T; Kamiya K; Ohba K; Nakamura S
    Jpn J Cancer Res; 2000 Jul; 91(7):748-52. PubMed ID: 10920283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.
    Warren RS; Yuan H; Matli MR; Gillett NA; Ferrara N
    J Clin Invest; 1995 Apr; 95(4):1789-97. PubMed ID: 7535799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and characterization of neutralizing monoclonal antibodies to human vascular endothelial growth factor/vascular permeability factor121 (VEGF/VPF121).
    Asano M; Yukita A; Matsumoto T; Matsuo K; Kondo S; Suzuki H
    Hybridoma; 1995 Oct; 14(5):475-80. PubMed ID: 8575796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 681.